Beat the giant: case of a giant prolactinoma during pregnancy on cabergoline.

Endocrinol Diabetes Metab Case Rep

Obesity, Endocrine, and Metabolism Center, King Fahad Medical City, Riyadh, Saudi Arabia.

Published: August 2018

Unlabelled: Giant prolactinomas are a rare entity; during pregnancy, the risk for complications associated with these tumors is higher. Here, we report a case of a young woman who had an invasive, giant prolactinoma post resection with residual disease who became pregnant. This patient was treated with cabergoline to prevent tumor expansion in pregnancy, resulting in the uneventful delivery of a healthy baby boy.

Learning Points: Giant prolactinoma can cause both diagnostic and therapeutic challenges given their atypical presentation.Accurate diagnosis is paramount to avoid unnecessary surgical intervention or pituitary irradiation.This case demonstrates the effectiveness and safety of CAB therapy during pregnancy.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6109208PMC
http://dx.doi.org/10.1530/EDM-18-0099DOI Listing

Publication Analysis

Top Keywords

giant prolactinoma
12
beat giant
4
giant case
4
giant
4
case giant
4
pregnancy
4
prolactinoma pregnancy
4
pregnancy cabergoline
4
cabergoline unlabelled
4
unlabelled giant
4

Similar Publications

Background: Giant prolactinoma (size > 4 cm) is a rare condition and accounts for less than 1% of pituitary adenomas. In even rarer cases, these lesions may involve craniocervical structures requiring surgical intervention. The present case is the largest reported giant prolactinoma (99 × 72 × 57 mm).

View Article and Find Full Text PDF

Pituitary macroadenomas are neuroendocrine tumors residing in the base of the skull. First-line therapies for prolactin-secreting adenomas (prolactinoma) include medical treatment with dopamine agonists and neurosurgical intervention. Cerebrospinal fluid (CSF) rhinorrhea is a well-known complication following skull base tumor treatment; however, spontaneous CSF rhinorrhea as the initial presenting feature of such tumors is rare.

View Article and Find Full Text PDF
Article Synopsis
  • Surgery is no longer the primary treatment for prolactinomas according to current guidelines, yet it's still important for certain cases, particularly those with complications or resistant to medication.
  • The study analyzed 12 patients who underwent endoscopic transsphenoidal surgery for prolactinomas between 2013 and 2022, focusing on surgical indications, outcomes, and complications.
  • Results showed that most patients had prior treatment with dopamine agonists and experienced complications like transient diabetes insipidus, with surgery effectively recommended for those with neurological symptoms or treatment failures.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!